GlassScriptPhysician profile
Ross S Hansen
NPI 1679702815
$12,128.43
in general payments reported to CMS, 2019-2025
29 companies · $363 in 2025
The $363 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $377 · 2022: $533 · 2023: $490 · 2024: $10K · 2025: $363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $10K · Food and Beverage: $1,219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $10,000.00 |
| Food and Beverage | $1,218.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $10,000.00 | 2024 | |
| Abbvie INC. | $450.88 | 2021-2024 | |
| Amgen INC. | $296.39 | 2021-2025 | Evenity, Prolia, Otezla |
| Novo Nordisk INC | $296.16 | 2021-2025 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $187.22 | 2023-2025 | Veozah, Myrbetriq |
| Lilly USA, LLC | $133.36 | 2021-2024 | Mounjaro |
| Pfizer INC. | $105.78 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.25 | 2021-2022 | |
| Daiichi Sankyo INC. | $54.04 | 2021 | |
| Novartis Pharmaceuticals Corporation | $53.73 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $49.61 | 2022-2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $49.31 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $35.60 | 2021-2023 | Fasenra |
| Biohaven Pharmaceuticals, INC. | $33.94 | 2021 | |
| Idorsia Pharmaceuticals US INC | $30.11 | 2022-2023 | Quviviq |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $27.98 | 2022 | |
| Glaxosmithkline, LLC. | $27.87 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.01 | 2025 | Caplyta |
| Chiesi USA, INC. | $19.94 | 2023 | Cleviprex |
| Genzyme Corporation | $17.85 | 2025 | |
| Dexcom, INC. | $17.70 | 2025 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $17.02 | 2022 | |
| Biogen, INC. | $16.76 | 2022 | |
| Rhythm Pharmaceuticals, INC. | $15.85 | 2023 | Imcivree |
| E.R. Squibb & Sons, L.L.C. | $15.79 | 2021 | |
| Exact Sciences Corporation | $15.74 | 2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $15.14 | 2022 | |
| Organogenesis INC. | $15.01 | 2022 | |
| Janssen Pharmaceuticals, INC | $11.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ross Hansen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.